On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products issued a positive opinion for a new formulation of COMIRNATY (COVID-19 vaccine, mRNA).

The new formulation did not require the dilution of the concentrate and was available in a 10-vial (60 dose) pack size, therefore, helps ensure simplified handling of the vaccine. In addition, the new formulation allows for longer storage.